SRR8518360
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- MYC_TARGETS_V1+0.570
- MYC_TARGETS_V2+0.530
- INTERFERON_ALPHA_RESPONSE+0.510
- G2M_CHECKPOINT+0.500
- DNA_REPAIR+0.460
- MTORC1_SIGNALING+0.420
- OXIDATIVE_PHOSPHORYLATION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.370
- INTERFERON_GAMMA_RESPONSE+0.340
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.360
- UV_RESPONSE_DN-0.350
- ESTROGEN_RESPONSE_EARLY-0.300
- TGF_BETA_SIGNALING-0.270
- NOTCH_SIGNALING-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- HEME_METABOLISM-0.240
- BILE_ACID_METABOLISM-0.230
- WNT_BETA_CATENIN_SIGNALING-0.220
- APICAL_SURFACE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518323 | — | E | 0.895 |
| 2 | SRR11296765 | — | — | 0.880 |
| 3 | SRR27320678 | — | — | 0.873 |
| 4 | 20020093.Her2HRneg | — | E | 0.869 |
| 5 | SRR17866821 | — | — | 0.867 |
| 6 | BS_MMNRZ1EQ | ATRT | — | 0.861 |
| 7 | TCGA-T3-A92N-01A-11R-A39I-07 | — | — | 0.861 |
| 8 | TCGA-AR-A0TU-01A-31R-A109-07 | — | E | 0.860 |
| 9 | 9a1be9ca-1641-4eac-beb9-3b54ec277a7c | — | — | 0.860 |
| 10 | SRR8518289 | — | E | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.460 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |